Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (191-200 of 377) with videos related to

Pageof 38
Sort By:
Clinical Lung Cancer|May 26, 2022
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung CancerSalma K Jabbour, Byoung Chul Cho, Emilio Bria, et al.
Cancers|March 14, 2020
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR InhibitorsAntonia Strippoli, Alessandra Cocomazzi, Michele Basso, et al.
Clinical Breast Cancer|July 19, 2014
Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxelEmilio Bria, Jenny Furlanetto, Luisa Carbognin, et al.
Cancer Treatment Reviews|June 1, 2014
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trialsEmilio Bria, Luisa Carbognin, Jenny Furlanetto, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancerCarmine Carbone, Geny Piro, Antonio Agostini, et al.
Immunotherapy|June 4, 2019
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysisAntonio Rossi, Vincenzo Di Noia, Anastasios Gkountakos, et al.
Therapeutic Advances in Medical Oncology|June 7, 2023
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trialsLuca Mastrantoni, Giovanna Garufi, Elena Di Monte, et al.
Biomedicines|October 27, 2022
Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic BiomarkerChiara Bazzichetto, Michele Milella, Ilaria Zampiva, et al.
Targeted Oncology|September 1, 2018
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate CancerRoberto Iacovelli, Chiara Ciccarese, Claudia Mosillo, et al.
ESMO Open|May 20, 2020
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcomeIlaria Trestini, Isabella Sperduti, Marco Sposito, et al.
Pageof 38

Showing results (191-200 of 377) with videos related to

Sort By:
Pageof 38
Clinical Lung Cancer|May 26, 2022
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung CancerSalma K Jabbour, Byoung Chul Cho, Emilio Bria, et al.
Cancers|March 14, 2020
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR InhibitorsAntonia Strippoli, Alessandra Cocomazzi, Michele Basso, et al.
Clinical Breast Cancer|July 19, 2014
Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxelEmilio Bria, Jenny Furlanetto, Luisa Carbognin, et al.
Cancer Treatment Reviews|June 1, 2014
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trialsEmilio Bria, Luisa Carbognin, Jenny Furlanetto, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancerCarmine Carbone, Geny Piro, Antonio Agostini, et al.
Immunotherapy|June 4, 2019
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysisAntonio Rossi, Vincenzo Di Noia, Anastasios Gkountakos, et al.
Therapeutic Advances in Medical Oncology|June 7, 2023
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trialsLuca Mastrantoni, Giovanna Garufi, Elena Di Monte, et al.
Biomedicines|October 27, 2022
Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic BiomarkerChiara Bazzichetto, Michele Milella, Ilaria Zampiva, et al.
Targeted Oncology|September 1, 2018
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate CancerRoberto Iacovelli, Chiara Ciccarese, Claudia Mosillo, et al.
ESMO Open|May 20, 2020
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcomeIlaria Trestini, Isabella Sperduti, Marco Sposito, et al.
Pageof 38